A study to learn how well the drug larotrectinib works in adults with different solid cancers with a change in the genes called NTRK fusio
- Conditions
- Solid tumors harboring NTRK fusionTherapeutic area: Diseases [C] - Cancer [C04]MedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864MedDRA version: 23.0Level: PTClassification code 10081769Term: NTRK gene fusion overexpressionSystem Organ Class: 10010331 - Congenital, familial and genetic disorders
- Registration Number
- EUCTR2015-003582-28-PL
- Lead Sponsor
- Bayer Consumer Care AG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 214
1. Locally advanced or metastatic malignancy with an NTRK1, NTRK2 or
NTRK3 gene fusion, identified through molecular assays as routinely
performed at Clinical Laboratory Improvement Amendments (CLIA) or
other similarly certified laboratories. Subjects who have an NTRK gene
fusion identified in a lab where certification of the lab cannot be
confirmed by the Sponsor at the time of consent may have been enrolled
in Cohort 9 as per protocol versions 1.0 - 8.0. From protocol version 9.0:
CLIA or similar certification of the lab performing the fusion assay is
required. However, patients may be included after discussion with the
sponsor if the lab performing the fusion assay is not CLIA or similar
certified
2. Subjects who have received prior standard therapy appropriate for
their tumor type and stage of disease, or who have no satisfactory
alternative treatments and in the opinion of the Investigator, would be
unlikely to tolerate or derive clinically meaningful benefit from
appropriate standard of care therapy
3. Subjects must have at least one measurable lesion as defined by
RECIST v1.1. Subjects with solid tumors without Response Evaluation
Criteria in Solid Tumors, version 1.1 (RECIST v1.1) measurable disease
(e.g., evaluable disease only) had been eligible for enrollment to Cohort
8 as per protocol versions 1.0 - 8.0, regardless of tumor type. Subjects
with primary CNS tumors should meet the following criteria:
a. Have received prior treatment including radiation and/or
chemotherapy, with radiation completed > 12 weeks prior to C1D1 of
therapy, as recommended or appropriate for that central nervous system
(CNS) tumor type
b. Have = 1 site of bi-dimensionally measurable disease (confirmed by
magnetic resonance imaging [MRI] and evaluable by Response
Assessment in Neuro-Oncology (RANO) criteria), with the size of at least
one of the measurable lesions = 1 cm in each dimension and noted on
more than one imaging slice
c. Imaging study performed within 28 days before enrollment. If on
steroid therapy, the dose must be stable for at least 7 days immediately
before and during the imaging study
d. Must be neurologically stable based on stable neurologic exam for 7
days prior to enrollment
For subjects eligible for enrollment to bone health cohort, inclusion
criterion 3 is modified as the following:
e. Subjects must have at least one lesion at baseline (measurable or
non-measurable as defined by RECIST v1.1 or RANO criteria, as
appropriate to tumor type)
f. Subjects with primary CNS tumors must be neurologically stable based
on stable neurologic exam for 7 days prior to enrollment
4. At least 18 years of age
5. Performance Status: Eastern Cooperative Oncology Group (ECOG)
score of = 3. If enrolled with primary CNS tumor to be assessed by
RANO, Karnofsky Performance Score (KPS) = 50%
6. Tumor tissue before treatment (mandatory). If neither fresh tissue
can be obtained nor archival tissue is available patients might be
enrolled after consultation with the sponsor
7. Adequate organ function as defined by the following criteria:
a. Serum aspartate transaminase (AST) and serum alanine transaminase
(ALT) < 2.5 × upper limit of normal (ULN), or AST and ALT < 5 × ULN if
liver function abnormalities are due to underlying malignancy
b. Total bilirubin < 2.5 × ULN, except in the setting of biliary obstruction.
Subjects with a known history of Gilberts Disease and an isolated
elevation of indirect bilirubin are eligible
c. Serum creatinine < 2.0 × ULN OR an
1. Investigational agent or anticancer therapy within 2 weeks prior to planned start of larotrectinib or 5 half-lives, whichever is shorter, and without recovery of acute and/or clinically significant toxicities from that therapy.
2. Prior progression while receiving approved or investigational tyrosine kinase inhibitors targeting TRK. Subjects who received less than 28 days of treatment and discontinued because of intolerance or toxicity are eligible.
3.Symptomatic or unstable brain metastases. (Note: Subjects with asymptomatic brain metastases are eligible to participate in the study). Subjects with primary CNS tumors are eligible.
4. Uncontrolled concurrent malignancy that would limit assessment of efficacy of larotrectinib. Allowed conditions may include but are not limited to in situ cancers of cervix, breast, or skin, superficial bladder cancer, limited stage prostate cancer, basal or squamous cancers of the skin.
5.Active uncontrolled systemic bacterial, viral, or fungal infection, CTCAE
grade = 2; unstable cardiovascular disease or other systemic disease
that would limit compliance with study procedures.
Unstable cardiovascular disease is defined as:
a. In adults, persistently uncontrolled hypertension defined as systolic
blood pressure (BP) > 150 mmHg and/or diastolic BP > 100 mmHg
despite antihypertensive therapy.
b. Myocardial infarction within 3 months of screening
c. Stroke within 3 months of screening
6. Inability to discontinue treatment with a strong CYP3A4 inhibitor or inducer (refer to Appendix C in section 12.3) prior to start of treatment initiation.
7. Pregnancy or lactation.
8. Currently recovering from adverse events (AEs) or adverse drug
reactions (ADRs) due to previous treatments. Inclusion is only advised
once the pre-existing AE/ADR resolves or recovers to baseline or at least
to CTCAE grade 1.
9. Known or suspected hypersensitivity against the active substance or any of the ingredients of the investigational medicinal product (IMP).
10. Known history of human immunodeficiency virus (HIV) infection. All patients must be screened for HIV up to 28 days prior to study drug start using a blood test for HIV according to local regulations.
11. Hepatitis B (HBV) or C (HCV) infection. All patients must be screened
for HBV and HCV up to 28 days prior to study drug start using the routine
hepatitis virus laboratorial panel. Patients positive for hepatitis B surface
antigen (HBsAg) or hepatitis B core antibody (HBcAb) will be eligible if
they are negative for HBV-DNA. Patients positive for anti-HCV antibody
will be eligible if they are negative for HCV-RNA.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method